Serial Number

09/272,734

Filing Date

Inventor

27 January 1999

Christopher J. Kolanko Mark D. Pyle

NOTICE

The above identified patent application is available for licensing. Requests for information should be addressed to:

OFFICE OF NAVAL RESEARCH DEPARTMENT OF THE NAVY CODE 00CC ARLINGTON VA 22217-5660

DISTRIBUTION STATEMENT A

Approved for Public Release Distribution Unlimited

19990520 040

DTIC QUALITY INSPECTED 4

 (\cdot)

1

PATENT APPLICATION

 $\left(\begin{array}{c} \\ \end{array} \right)$

 $\mathcal{I}_{\mu\nu}$

2	
3	GENOMIC DNA HYBRIDIZATION PROBE AND IMMUNOENZYMATIC COLOR
4	PIGMENT DETECTION ASSAY
5	
6	Background of the Invention
7	1. Field of the Invention
8	The invention relates generally to an assay method and composition for determining genetic
9	toxicity. More particularly, the invention relates to a whole genomic DNA probe and to a method
10	for using the DNA probe in a micronucleus assay.
11	2. Description of the Related Art
12	The mouse bone marrow micronucleus assay is used for the detection of damage to
13	chromosomes or mitotic apparatus induced by particular compounds such as pharmaceutical drugs,
14	environmental chemical agents, etc. (see, for example, Schmid, W. "The Micronucleus Test",
15	Mutation Res. 31, 9 (1975), Salamone, et al., "Towards an Improved Micronucleus Test: Studies
16	on 3 Model Agents, Mitomycin C, Cyclophosphamide and Dimethylbenzanthracene:" Mutation Res.
17	74, 347 (1980), and Heddle, J. A., et al. "The Induction of Micronuclei as a Measure of
18	Genotoxicity: A Report of the U.S. Environment Protection Agency Gene-Tox Program, Mutation
19	Res. 123, 61 (1983), Salamone, M. F. all incorporated herein by reference). The test is based on
20	the observation that mitotic cells with chromatid breaks or chromatid exchanges exhibit disturbances

PATENT APPLICATION

(

	-
1	in the anaphase distribution of their chromatin. After telophase, this displaced chromatin can be
2	excluded from the nuclei of the daughter cells and is found in the cytoplasm as a micronucleus.
3	In the conventional mouse bone marrow micronucleus assay, mice are exposed to a particular
4	test substance, and then bone marrow cells of the exposed animals are isolated. The isolated cells
5	are immediately smeared onto a slide, stained with a reagent and examined under a microscope for
6	the presence of micronuclei. Giemsa stain has traditionally been used as the staining reagent;
7	however, because of the tendency of Giemsa stain to stain artifacts that resemble micronuclei, DNA-
8	specific fluorescent stains such as acridine orange are now being used. See, for example, Hayashi,
9	M., Sofuni, T. and Ishidate, M. Jr. 1983, "An application of acridine orange fluorescent staining to
10	the micronucleus test". Mutat. Research, 120:241-247; Hayashi, M., Morita, T., Kodama, Y.,
11	Sofuni, T. and Ishidate, M. Jr. 1990, "The micronucleus assay with mouse peripheral blood
12	reticulocytes using acridine orange-coated slides" Mutat. Research, 245:245-249 and MacGregor,
13	J.T., Wehr, C.M. and Langlois, R.G. 1983, "A simple fluorescent staining procedure for
14	micronucleus and RNA in erythrocytes using Hoechst 33258 and pyronin Y" Mutat. Research,
15	120:269-275, all incorporated herein by reference.
16	DNA-specific fluorescent stains used in the mouse bone marrow micronucleus assay have

16 DNA-specific fluorescent stains used in the mouse bone marrow micronucleus assay have 17 several disadvantages that limit their usefulness. First, fluorescent microscopy requires expensive, 18 specialized fluorescent microscopes equipped with special multi-filter cube switching and low light 19 level video hardware. Fluorescent microscopes require a high degree of technical sophistication to 20 use effectively. Second, fluorescent-stained slides fade over time and therefore cannot be stored and

Inventor's Name: Christopher J. Kolanko and Mark D. Pyle

PATENT APPLICATION

 $\mathcal{L}_{\mathcal{F}} \rightarrow$

archived for future reference. Third, color signatures achieved by fluorescent detection may be
 unstable due to differential fluorescent bleaching rates. Fourth, automation of the finding and
 scoring of fluorescent stained micronuclei is costly and difficult. Finally, fluorescent preparations
 may cause swelling of chromosomes and loss of fine detail.

Thus, there is a need for a method for detecting micronuclei that allows the use of standard 5 light field microscopy equipment and does not require expensive, specialized fluorescent microscopy 6 equipment. Moreover, there is a need for a method of detecting micronuclei that provides a 7 permanent record of the assay that can be stored and archived. Moreover, there is a need for a 8 method of detecting micronuclei that produces a stable color signature. Moreover, there is a need for 9 a method of detecting micronuclei wherein the finding and scoring of micronuclei can be easily 10 automated. Moreover, there is a need for a method of detecting micronuclei that does not cause the 11 swelling of chromosomes. 12

13

Summary of the Invention

14 It has now been found that micronuclei in cells may be detected by means of a whole 15 genomic DNA probe coupled with immunoenzymatic color pigment detection.

In particular, the invention provides a method for detecting the presence of micronuclei in cells of an organism. According to the method of the invention, cells of an organism are isolated and exposed to a hybridization probe of digested labeled, whole genomic DNA. The hybridization probe is labeled with a first binding member that allows it to bind specifically to a second binding member. The hybridization probe hybridizes with DNA in the cells, including DNA contained in micronuclei,

(

PATENT APPLICATION

1	if present. The hybridization probe is detected by exposing the cells to a compound comprising the
2	second binding member coupled to an enzyme capable of reacting with a chromogenic substrate to
3	convert the chromogenic substrate into a colored pigment. The compound binds to the first binding
4	member. When the cells are exposed to a chromogenic substrate, the chromogenic substrate is
5	converted into a colored pigment, thereby indicating the presence and location of DNA in the cells.
6	The presence of micronuclei is indicated by the presence of colored pigment outside the nucleus of
7	the cells. The cells are then examined and scored for the presence or absence of micronuclei.
8	In another aspect, the invention provides a hybridization probe for detecting micronuclei in
9	mouse cells, the hybridization probe being made by digesting whole genomic mouse DNA into
10	DNA fragments and then labeling the DNA fragments.
11	In another aspect, the invention provides a test kit for assaying cells for the presence of
12	micronuclei, the test kit comprising
13	(a) a hybridization probe, the hybridization probe comprising digested, labeled whole genomic
14	DNA, the digested genomic DNA being labeled with a first binding member capable of
15	specifically binding with a second binding member,
16	(b) a compound comprising the second binding member coupled to an enzyme capable of
17	reacting with a chromogenic substrate to convert the chromogenic substrate into a colored
18	pigment, and
19	(c) a chromogenic substrate.
20	The invention overcomes the above-described disadvantages of the conventional fluorescent

PATENT APPLICATION

· · · · · ·

Inventor's Name: Christopher J. Kolanko and Mark D. Pyle

staining in a micronucleus assay. The use of a DNA-specific whole genomic DNA hybridization 1 probe minimizes the staining of cell artifacts and thereby minimizes false positive results in the 2 micronucleus assay. The colored pigment used in the detection of micronuclei can be visualized 3 using standard light field microscopy, and expensive specialized fluorescent microscopes is not 4 5 needed. Brightfield illumination may be used instead of epi-illumination (which is required to excite flurescence preparations and which is more uneven). The colored pigment used in the invention 6 allows for permanent staining of cells, which allows for assay slides to be stored, archived and 7 reanalyzed for years. The color signatures used in color pigment detection according to the present 8 invention are more stable than fluorescent preparations and there is less variation in intensity of 9 labeled elements within fields of view and between fields. The automation of finding and scoring 10 of micronuclei is more easily achieved. The method of hybridization and color pigment staining of 11 the present invention is less likely to cause swelling of chromosomes and loss of fine detail than 12 13 methods of fluorescent staining.

14

Description of the Preferred Embodiments

Micronuclei may form in cells of an animal that is exposed to a genetically toxic substance or environment. The micronucleus assay, which involves exposing an animal to a particular substance or environment, then isolating cells from the animal and examining them for the presence of micronuclei, is a method for screening drugs and chemical agents to determine their genetic toxicity. See, for example, U.S. Patent No. 5,229,265 to Tomesko; Parton, J.W., Probst, G.S. and Garriot, M.L. 1988, "The in vivo effect of 2,6-xylidine on induction of micronuclei in mouse bone

ţ

Inventor's Name: Christopher J. Kolanko and Mark D. Pyle

PATENT APPLICATION

was mining about the fact the best being and and and and

()

marrow cells", Mutat Research 206:281-283; Parton, J.W., Garriott, M.L. and Beyers, J.E. 1991,
"Expulsion of demecolcine induced micronuclei from mouse bone marrow polychromatic
erythrocytes", Environ. and Molecular Mutagenesis 17:79-83; Styles, J.A., Richardson, C.R. and
Burlinson, B. 1983, "A comparison of the incidence of micronuclei in blood and bone marrow in
three strains of mouse dosed with cyclophosphamide or hexamethylphosphamide (HMPA)" Mutat
Research, 122:143-147, all incorporated herein by reference.

7 The formation of a micronucleus in a cell exposed to a genetically toxic agent is the result 8 of breakage of a chromatid or chromosome or the result of lagging of one or more whole 9 chromosomes at anaphase. Because the event is random, that is, because there is no way to predict 10 in advance which portion of which chromosome will break or lag to form a micronucleus, the present 11 invention uses whole genomic DNA as a hybridization probe to detect DNA outside the nucleus of 12 the cell. Before use as a hybridization probe, the whole genomic DNA is digested and labeled.

Whole genomic DNA may be obtained by any known means of isolating whole genomic
DNA. See, for example, Sambrook, J., Fritsch, E.F. and Maniatis, T. 1989, Molecular Cloning, A
Laboratory Manual, 2nd Edition, Cold Springs Harbor Laboratory Press, Colds Spring Harbor, NY.
For many species, whole genomic DNA is commercially available. For example, human, rat and
mouse genomic DNA is available from Promega, Madison, WI.

18 So that the whole genomic DNA can move about cells easily and hybridize with any 19 fragment of DNA that may be contained in a micronucleus, the whole genomic DNA is digested with 20 a restriction enzyme before it is used as a hybridization probe. Preferably, the whole genomic DNA

Inventor's Name: Christopher J. Kolanko and Mark D. Pyle

(Eg

PATENT APPLICATION

- is digested with DNase I for a sufficient time to cut the genomic DNA into fragments of about 100 1 2 base pairs (bp) to about 1000 base pairs. An additional aspect of the present invention is the use of enzyme-linked labels that produce 3 an insoluble precipitate for the detection of the fragments of the whole genomic DNA in cells. To 4 enable the use of enzyme-linked labels, the digested fragments of the whole genomic DNA are 5 labeled with a functional group that is capable of binding to a binding partner that is linked to the 6 enzyme. For example, the fragments of DNA may be labeled with biotin and the enzyme may be 7 linked to avidin or strepavidin, which have a strong binding affinity to biotin. The labeling of the 8 DNA fragments may be accomplished by any method known in the art, including, for example, nick 9 translation to incorporate labeled nucleotides into the fragments of DNA. 10 In the method of the present invention, cells of an organism are isolated, preferably by 11 spreading onto microscope slides. The cells are exposed to the labeled, digested whole genomic 12 DNA so that the whole genomic DNA fragments hybridize to cellular DNA, including the DNA of 13 micronuclei, if present. Methods known in the art for hybridizing DNA probes to cellular DNA may 14 be used. See, for example, Haar, F-M, Markus D., Michael H., Horst L. and Cremer, C. 1996, 15 "Optimization of Fast-FISH for alpha-satellite DNA Probes" J Biochem. Biophys. Methods 33:43-16 54., incorporated herein by reference. The cells are then exposed to the enzyme, which is coupled 17 to a functional group that causes the enzyme to bind to the whole genomic DNA fragments. The cells 18
- are then exposed to a chromogenic substrate of the enzyme, which creates an insoluble color pigment
 precipitate that identifies the location of the whole genomic DNA fragments. Micronuclei, if present

Inventor's Name: Christopher J. Kolanko and Mark D. Pyle

PATENT APPLICATION

in the cells, may be detected by examining the cells for the presence of color pigment outside of the 1 nucleus. A counterstain such as Wright's Giesma stain may be added to aid in the differentiation of 2 cell types and in the identification of micronuclei. Preferably, the examination of the cells for the 3 presence of micronuclei is done by brightfield microscopy. The step of scoring the cells may be 4 accomplished by any means of making note of cells that contain micronuclei. The cells may then be 5 scored according to the presence or absence of micronuclei. The method of the present invention, 6 particularly the process of examining and scoring the cells may be automated and computer 7 controlled. The slides may then be archived for future reference. 8

Any binding partners, enzymes and substrates known in the art for enzymatic labeling and 9 detection and for creating permanent stains may be used in the present invention. Preferably, the 10 enzyme is a peroxidase, such as horse radish peroxidase, or alkaline phosphatase. Chromogenic 11 substrates for horse radish peroxidase include 3,3',5,5' tetramethylbenzidine (TMB), 3,3'-12 diaminobenzidine (DAB), and 3-amino-9-ethyl carbazol (AEC). Chromogenic substrates for alkaline 13 phosphatase include BCIP/NBT, Fast Red and AP-Orange. Avidin-linked enzymes and chromogenic 14 substrates are commercially available from, for example, Pierce Chemical Company (Rockville, IL) 15 and Sigma (St. Louis, MO). Enzymatic labeling and detection are described, for example, in U.S. 16 Patent No. 4,789,630 to Bloch et al and in Pierce Chemical Company, 94-95 Pierce Catalog and 17 Handbook, Rockville, IL 1994, pages T-209 to T-230, both incorporated herein by reference. 18 The following table provides typical enzyme-substrate pairs that can be used in the method 19

20 of the present invention:

PATENT APPLICATION

1 TABLE 1. Enzyme linked immunostaining detection of either horseradish peroxidase (HRP)

- 2 or alkaline phosphatase (Alk Phase).
- 3

4	ENZYME	SUBSTRATE	BRIGHTFIELD
5	LABEL		COLOR
6	HRP	3,3-Diaminobenzidine	Brown
7	HRP	(DAB) Aminoethylcarbozole	Red
8	HRP	(AEC) Tetramethylbenzidine	Green
9	Alk Phase	(TMB) BCIP/NBT	Purple
10	Alk Phase	Fast Red TR	Red
11	Alk Phase	AP-Orange	Orange

12

An advantage of using color pigment staining is that, unlike fluorescent-stained slides which
fade after a few weeks, color pigment-stained slides are permanent and may be archived for future
reference.

16 Having described the invention, the following examples are given to illustrate specific
17 applications of the invention including the best mode now known to perform the invention. These
18 specific examples are not intended to limit the scope of the invention described in this application.

PATENT APPLICATION

1 EXAMPLE 1

2 Preparation of bone marrow slides from the excised femurs of cyclophosphamide-treated mice and evaluation of micronucleated polychromatic erythrocytes were conducted as described by 3 Parton, J.W., Probst, G.S. and Garriot, M.L. 1988, "The in vivo effect of 2,6-xylidine on induction 4 5 of micronuclei in mouse bone marrow cells" Mutat Research 206:281-283, incorporated herein by reference. The iliac end of the excised femurs was removed and a 00 sable hair brush, wetted with 6 fetal bovine serum (Gibco, Grand Island, NY), was inserted into the marrow canal and rotated back 7 and forth. The sample was streaked onto a microscope slide. The procedure was repeated until four 8 streaks were made from the femur, according to the procedure described in Styles, J.A., Richardson, 9 C.R. and Burlinson, B. 1983, "A comparison of the incidence of micronuclei in blood and bone 10 marrow in three strains of mouse dosed with cyclophosphamide or hexamethylphosphamide 11 (HMPA)" Mutat Research, 122:143-147, incorporated herein by reference. 12 13 The mouse micronucleus probe was synthesized by taking whole mouse genomic DNA

(Promega, Madison WI) and extensively digesting with 0.0005 units/µl DNase I (Sigma, St Louis,
MO) at 37° C for 10 minutes followed by DNase inactivation at 70° C for 10 minutes. (At this point
the digested DNA can be stored at -20° C indefinitely.) One µgram of the digested mouse genomic
DNA was nick translated in a reaction mixture containing 5.0 µl of 0.53 mM biotin-14-dUTP
(Boehringer Mannheim, Indianapolis, IN), 1.0 µl of 10 U/µl Polymerase I (Sigma), 10 µl solution
of 0.2 mM dNTP's (dTTP, dGTP, dCTP (Boehringer Mannheim) in a solution of 500 mM Tris (pH
8.0), 50 mM MgCl₂, 100 mM 2-mercaptoethanol, 100 µg bovine serum albumin) in a total volume

PATENT APPLICATION

Inventor's Name: Christopher J. Kolanko and Mark D. Pyle

of 100 µl (Sambrook et al., 1989). The reaction was incubated at 15° C for 2 hours and stopped with 1 6 µl of 500 mM EDTA. Biotin-labeled DNA was separated from unincorporated nucleotides with 2 a Sephadex G-50 spin column. The labeled-probe was hybridized by the Fast-hybridization 3 procedure, following the procedure described in Haar, F-M, Markus D., Michael H., Horst L. and 4 Cremer, C. 1996, "Optimization of Fast-FISH for alpha-satellite DNA Probes", J Biochem. Biophys. 5 Methods 33:43-54, to mouse bone marrow slides previously fixed in 100% methanol for 30 minutes 6 and then allowed to air dry for 20 minutes. The mouse genomic probe (0.10 µg) was added to the 7 Fast-hybridization buffer mixture (3 µl working hybridization buffer (100mmol Tris-HCl; 30 mmol 8 MgCl₂; 500mmol KCl; 10 mg gelatin; pH 8.3 at 20° C) plus 3 µl 20X SSC (saline sodium citrate) 9 and 24 μ l distilled H₂0 total volume of buffer is 30 μ l) and applied to the mouse bone marrow 10 spreads. The slide was coversliped, all air bubbles were removed, and the edges of the coverslip 11 were sealed with rubber cement. Each slide was incubate for 5 minutes at 70°C on a heating block 12 to denature both cellular and probe DNA and then immediately placed on a second heating block 13 pre-equilibrated to 37 C° for 55 minutes. After Fast-hybridization the coverslip was removed and 14 the slides were quickly placed in a solution of 1X PBS/0.2% Tween-20 for 5 minutes at room 15 temperature and then blocked in a solution of 1% non-fat dry milk in sterile filtered 1X PBS at 37 16 17 C° for 1 hour. Just prior to immunostaining probe detection slides were washed in 1X PBS for 5 minutes and then followed by the addition of 200 µl of avidin-horse radish peroxidase (Avidin-HRP) 18 19 (Sigma) diluted in sterile filtered 1X PBS (1:10,000 dilution). Each slide was coversliped and incubated in a humidity chamber at 37° C for 1 hour. After incubation the slides were washed in 1X 20

Inventor's Name: Christopher J. Kolanko and Mark D. Pyle

PATENT APPLICATION

();;

PBS, 3X for 5 minutes at room temperature (slides can be stored in 1X PBS at 4° C before
 development) followed by immunoenzymatic probe detection with the compound
 aminoethylcarbazole (AEC) (Sigma) to form a red precipitate.

A stock solution of 0.4 grams of AEC was dissolved in 100 mls of dimethyl formamide 4 (Sigma) and stored at 4° C (stock solution can be stored for 2 months). Prior to probe detection 1 5 ml of AEC stock was added to 15 ml of 0.1 M sodium acetate (pH 5.2) and 15 µl of 30% hydrogen 6 peroxide. The AEC solution was filtered through a Whatman No. 1 filter and 100 µl was applied 7 directly to the slide and allowed to incubate for 10 minutes. AEC color detected slides were then 8 washed for 5 minutes in 1X PBS and then counterstained with either 4% Giemsa in phosphate buffer 9 or by the Wright's Giemsa staining technique according to Parton et al. 1988. The reaction of the 10 HRP with AEC and peroxide formed a dark red precipitate that aided in detection of both the cellular 11 DNA and micronuclei found within the PCE and NCE cells. When counterstained with Wright's 12 13 Giemsa, a dark red coloration of the DNA by the probe is observed in both the micronuclei and in 14 the intracellular DNA.

15 EXAMPLE 2

The procedures of Example 1 were repeated, except that 3'3-Diaminobenzidine (DAB) was
used instead of AEC. 0.025 grams of 3'3-diaminobenzidine was dissolved in 40 ml of 0.05 M Tris
buffer (pH 7.6) and 8.3 µls of 30% hydrogen peroxide followed by filtering through a Whatman No.
1 filter paper. Each slide was immersed in DAB solution for 5 minutes and the reaction stopped by
placing the slides in 1X PBS for 5 minutes followed by counterstaining. The DAB formed a a

PATENT APPLICATION

- l brown to black precipitate.
- 2 Obviously, many modifications and variations of the present invention are possible in light
- 3 of the above teachings. It is therefore to be understood that
- 4 the invention may be practiced otherwise than as specifically described.

PATENT APPLICATION

ABSTRACT

A method for detecting the presence of micronuclei in cells of an organism comprises the steps of

(a) isolating cells of the organism,

(b) exposing the cells to a hybridization probe, the hybridization probe comprising digested, labeled whole genomic DNA, the digested genomic DNA being labeled with a first binding member capable of specifically binding with a second binding member, whereby, as a result of exposing the cells to the hybridization probe, the hybridization probe binds hybridizes with DNA in the cells, including DNA contained in micronuclei, if present,

(c) exposing the cells to a compound comprising the second binding member coupled to an enzyme capable of reacting with a chromogenic substrate to convert the chromogenic substrate into a colored pigment,

whereby, as a result of exposing the cells to the compound, the compound binds to the hybridization probe that is hybridized with the DNA in the cells,

(d) exposing the cells to the chromogenic substrate,

whereby the chromogenic substrate is converted into a colored pigment in the presence of the enzyme, and

(e) examining the cells and scoring the cells for the presence or absence of micronuclei.